Proactiveinvestors recommends
Additional Information
Market: AIM
Sector: Support Services
EPIC: FIP
Latest Price: 60.00  (0,00%)
52-week High: 78.50
52-week Low: 42.50
Market Cap: 65.66M
1 year chart
digital-look imported chart image
1 day chart
digital-look imported chart image
Fusion IP
www.fusionip.co.uk

Fusion IP owns the rights to 100% of university-owned research generated at two of the UK's leading universities – The University of Sheffield and Cardiff University. These exclusive partnerships enable us to develop some of the world's most advanced and exciting science, in fields as varied as clean energy, electronics, engineering and medicine; turning world class research into valuable businesses through the creation of portfolio of companies.

Full Fusion IP profile here
Pdf

Fusion IP says phase 2 trial for Diurnal's Chronocort underway

17th Jan 2013, 10:26 am by Philip Whiterow
The CATCH trial is a Phase 2 study in patients suffering from congenital adrenal hyperplasia. The CATCH trial is a Phase 2 study in patients suffering from congenital adrenal hyperplasia.

Diurnal, one of Fusion IP's (LON:FIP) portfolio of companies, has begun the phase 2 trial for its lead product Chronocort.

The first patient has been enrolled into the CATCH trial, which is aimed at people suffering from reduced levels of the key hormone cortisol (hydrocortisone).

Chronocort is a modified release therapy that delivers hydrocortisone in a manner that mimics the body's normal circadian rhythm (the body's natural 24 hour hormone cycle).

Diseases that stem from cortisol deficiency include congenital adrenal hyperplasia and adrenal insufficiency, each of which requires life-long treatment.

The CATCH trial is a Phase 2 study in patients suffering from congenital adrenal hyperplasia and is being run by the National Institute of Health (NIH), Maryland, US. The estimated completion date is mid-2013.

Chronocort has already received two related orphan drug designations from the European Medicines Agency, which affords ten years of market exclusivity after the grant of marketing authorisation in Europe.

Peter Grant, Fusion IP's operations director said: "The start of Phase 2 trials is tremendous news for Diurnal and we remain very excited about Diurnal's prospects.  Successful completion of the Phase 2 trial will be a significant value uplift event."

Martin Whitaker, Diurnal's chief executive, added: "The Chronocort programme remains a key focus for Diurnal and, if the results from the current trial are positive, we expect to progress the product to late stage clinical trials in Congenital Adrenal Hyperplasia and Adrenal Insufficiency."

Fusion IP specialises in the commercialisation of technology developed at Sheffield and Cardiff universities.

It shareholding in Diurnal is 43.1%.

No investment advice


Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".


You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.


You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.


From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.


You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here